Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CA-4948 + FOLFOX/PD-1 Inhibitor +/- Trastuzumab in Gastric and Esophageal Cancer
NCT05187182Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2023
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of emavusertib in gastric cancer (GC), esophageal cancer and gastroesophageal junction cancer (3 arms), sponsored by Washington University School of Medicine. Primary endpoints: Number of adverse events at 15 months and Expansion dose of CA-4948 at 19 months. Started Jun 2023; status: recruiting.
02
Drugs
emavusertib
03
Conditions
gastric cancer (GC)esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05187182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05187182.